Armata Pharmaceuticals, Inc.
ARMP
$1.91
-$0.10-4.98%
AMEX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 4.70M | 5.17M | 5.47M | 3.72M | 4.70M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.70M | 5.17M | 5.47M | 3.72M | 4.70M |
| Cost of Revenue | 47.96M | 50.54M | 49.64M | 49.46M | 49.24M |
| Gross Profit | -43.26M | -45.37M | -44.17M | -45.74M | -44.54M |
| SG&A Expenses | 13.26M | 13.18M | 13.04M | 13.38M | 12.29M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 45.10M | 47.61M | 46.94M | 45.78M | 44.47M |
| Operating Income | -40.40M | -42.44M | -41.48M | -42.06M | -39.77M |
| Income Before Tax | -426.00K | -18.92M | -41.36M | -67.04M | -79.58M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -0.43 | -18.92 | -41.36 | -67.04 | -79.58 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -426.00K | -18.92M | -41.36M | -67.04M | -79.58M |
| EBIT | -40.40M | -42.44M | -41.48M | -42.06M | -39.77M |
| EBITDA | -39.02M | -41.11M | -40.24M | -40.91M | -38.71M |
| EPS Basic | -0.01 | -0.52 | -1.15 | -1.86 | -2.20 |
| Normalized Basic EPS | -0.90 | -0.91 | -0.86 | -0.85 | -0.76 |
| EPS Diluted | -1.12 | -1.62 | -1.64 | -2.35 | -2.28 |
| Normalized Diluted EPS | -0.64 | -0.72 | -0.77 | -0.75 | -0.70 |
| Average Basic Shares Outstanding | 144.70M | 144.64M | 144.56M | 144.47M | 144.38M |
| Average Diluted Shares Outstanding | 212.99M | 189.63M | 166.65M | 166.56M | 164.86M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |